Herpes zoster: The rationale for the introduction of vaccination in Italy

Journal of Preventive Medicine and Hygiene

Volumn 56, Issue , 2015, Pages E33-E36

  Paganino, C ^a   Alicino, Cristiano ^a   Trucchi, C ^a   Albanese, E ^a   Sticchi, L ^a   Icardi, G ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Herpes zoster; Italy; Vaccine

Indexed keywords

VARICELLA ZOSTER VACCINE;

AGE DISTRIBUTION; BURDEN OF ILLNESS; COST EFFECTIVENESS ANALYSIS; DISEASE REGISTRY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DURATION OF PROTECTION; EPIDEMIOLOGICAL DATA; GENERAL ASPECTS OF DISEASE; HEALTH CARE CONCEPTS; HEALTH CARE COST; HERPES ZOSTER; HOSPITALIZATION RATE; HUMAN; IMMUNOGENICITY; INCIDENCE; ITALY; NONHUMAN; POSTHERPETIC NEURALGIA; REVIEW; TREND STUDY; VACCINATION;

EID: 84994545336     PISSN: 11212233     EISSN: 24214248     Source Type: Journal    
DOI: 10.15167/2421-4248/jpmh2015.56.1.473     Document Type: Review

References (25)

1. Cohen JI. Clinical practice: Herpes zoster. N Engl J Med 2013;369:255-63.
2. Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc 2009;84:274-80.
3. Johnson RW. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines 2010;9:21-6.
4. Watson P. Postherpetic neuralgia. Am Fam Physician 2011;84:690-2.
5. Schmader K, Gnann JW Jr, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008;197:S207-15.
6. Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010;8:37.
7. th Annual Meeting of the IHMF®, Lisbon, Portugal, 28-30 October 2005.
8. Whitley RJ, Shukla S, Crooks RJ. The identification of risk factors associated with persistent pain following Herpes Zoster. J Infect Dis 1998;178:S71-5.
9. Jung BF, Johnson RW, Griffin DR, et al. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004;62:1545-51.
10. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014;4:e004833.
11. Pinchinat S, Cebrián-Cuenca AM, Bricout H, et al. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis 2013;13:170.
12. Gialloreti LE, Merito M, Pezzotti P, et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis 2010;10:230.
13. Opstelten W, Mauritz JW, de Wit NJ, et al. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2002;19:471-5.
14. Di Legami V, Gianino MM, Ciofi degli Atti M, et al. Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. Vaccine 2007;25:7598-604.
15. Centers for Disease Control and Prevention (CDC). Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep 2014;63:729-31.
16. Centers for Disease Control and Prevention (CDC). Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep 2011;60:1528.
17. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84.
18. Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012;54:922-8.
19. Gabutti G, Franco E, Bonanni P, et al. Reducing the burden of Herpes Zoster in Italy. Hum Vaccin Immunother 2015;11:101-7.
20. Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012;55:1320-8.
21. Morrison VA, Johnson GR, Schmader KE, et al. Long-Term Persistence of Zoster Vaccine Efficacy. Clin Infect Dis 2015;60:900-9.
22. Li X, Zhang JH, Betts RF, et al. Modeling the durability of ZOSTAVAX(®) vaccine efficacy in people ≥ 60 years of age. Vaccine 2015;33:1499-505.
23. Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011;305:160-6.
24. Langan SM, Smeeth L, Margolis DJ, et al. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med 2013;10:e1001420.
25. Kawai K, Preaud E, Baron-Papillon F, et al. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review. Vaccine 2014;32:1645-53.